# Koya Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/koya-medical

- Industry: Medical Devices & Equipment
- Headquarters: Oakland, US
- Website: www.koyamedical.com
- Total disclosed funding: $41M
- Latest round: Series B (Dec 21, 2021)
- Investors on record: 9

## About

Koya Medical, Inc. is a US-based company specializing in the development of innovative medical devices for the management of venous and lymphatic diseases, primarily focusing on effective treatment solutions for conditions like lymphedema and edema.Koya Medical, Inc. was founded in 2018 in Oakland, US, focusing on the design of medical solutions for venous diseases. The company has evolved its strategy over time and has raised a total of USD 30.00 mn across 4 funding deals, with the latest being a Series B round led by 3x5 Partners on November 15, 2023. The founder, Andy Doraiswamy, has a background that includes previous ventures, although specific details on those are not available.Koya Medical specializes in innovative solutions for managing venous and lymphatic diseases, primarily through its flagship product, the Dayspring nonpneumatic compression device. This device provides effective treatment for lymphedema and edema, significantly reducing swelling and improving patients' quality of life. Koya's products are backed by clinical research and validated through multi-center trials, outperforming traditional pneumatic devices. The company serves healthcare providers, hospitals, and rehabilitation centers across North America, Europe, and select regions in Asia, ensuring broad accessibility for patients suffering from chronic venous diseases.Koya Medical generates revenue through the direct sale of its Dayspring compression devices as well as partnerships with healthcare institutions and specialty medical retailers. The company's B2B model facilitates bulk orders from medical facilities, which are often supported by training and resource materials to enhance treatment adherence. While specific pricing details are proprietary, Koya is committed to fostering long-term relationships with clients, which may include subscription-based support services for ongoing patient education and access to clinical data.In November 2023, Koya Medical, Inc. raised USD 30.00 mn in equity funding, led by OrbiMed Advisors. The company plans to utilize this funding to support its business expansion and continuous growth, particularly focusing on its Dayspring lymphedema treatment. Koya aims to introduce new products and expand into additional markets, although specific release dates and targeted regions for expansion have not been disclosed.

## Funding rounds

- Series B, Dec 21, 2021, $30M — Arboretum Ventures, Scientific Health Development, 503 Partners, Asahi Kasei Corporate Venture Capital, Cadence Healthcare Ventures
- Series A, Dec 15, 2020, $11M — Aphelion Capital, Arboretum Ventures, Scientific Health Development, Zuhlke Ventures, InnerProduct Partners, Bolt

## Investors

- Aphelion Capital (https://capitalatlas.ai/funds/aphelion-capital) — Series A
- Arboretum Ventures (https://capitalatlas.ai/funds/arboretum-ventures) — Series A, Series B
- Scientific Health Development (https://capitalatlas.ai/funds/scientific-health-development) — Series A, Series B
- Zuhlke Ventures (https://capitalatlas.ai/funds/zuhlke-ventures) — Series A
- InnerProduct Partners (https://capitalatlas.ai/funds/innerproduct-partners) — Series A
- Bolt (https://capitalatlas.ai/funds/bolt) — Series A
- 503 Partners (https://capitalatlas.ai/funds/503-partners) — Series B
- Asahi Kasei Corporate Venture Capital — Series B
- Cadence Healthcare Ventures — Series B